Royalty Pharma/$RPRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Ticker
- $RPRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- New York, United States
- Website
- www.royaltypharma.com
Royalty Pharma Metrics
BasicAdvanced
$28B
34.19
$1.86
0.43
$0.93
1.47%
Price and volume
Market cap
$28B
Beta
0.43
52-week high
$64.38
52-week low
$35.92
Average daily volume
3M
Dividend rate
$0.93
Financial strength
Current ratio
2.797
Quick ratio
2.786
Long term debt to equity
0.877
Total debt to equity
0.916
Dividend payout ratio (TTM)
49.15%
Interest coverage (TTM)
4.34%
Profitability
EBITDA (TTM)
1,557.375
Gross margin (TTM)
95.82%
Net profit margin (TTM)
32.02%
Operating margin (TTM)
61.22%
Revenue per employee (TTM)
$25,360,000
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
13.97%
Valuation
Price to earnings (TTM)
34.195
Price to revenue (TTM)
10.949
Price to book
4.16
Price to tangible book (TTM)
4.81
Price to free cash flow (TTM)
48.088
Free cash flow yield (TTM)
2.08%
Free cash flow per share (TTM)
1.326
Dividend yield (TTM)
1.45%
Forward dividend yield
1.47%
Growth
Revenue change (TTM)
10.01%
Earnings per share change (TTM)
-19.98%
3-year revenue growth (CAGR)
2.41%
3-year earnings per share growth (CAGR)
48.12%
3-year dividend per share growth (CAGR)
5.27%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Analyst projections of the future price of Royalty Pharma stock.
Bulls say / Bears say
Royalty receipts rose 14% in Q2, and the company lifted 2026 portfolio-receipts guidance to $3.4bn–$3.5bn, its second increase this year. That points to stronger near-term income from the royalty portfolio. (Royalty Pharma)
Capital deployment exceeded $1bn in 2026 by early August, and the development pipeline reached 19 potential therapies. These investments broaden future royalty opportunities, although their returns depend on clinical and commercial success. (Royalty Pharma)
The business converts receipts into substantial cash with relatively low overhead: Q2 adjusted EBITDA rose 16% to $736m, while operating and professional costs were 4.8% of receipts. This leaves more cash available for new deals and shareholder returns. (The Motley Fool)
Competitive erosion is already visible: Q2 Promacta royalties fell 75% following US generic entry, while Imbruvica royalties fell 16%; management also expects pressure from a US Tysabri biosimilar. Growth in newer products must keep offsetting these declines. (Royalty Pharma, The Motley Fool)
Royalty exposure is concentrated in Vertex’s cystic-fibrosis franchise, which accounted for 30% of current royalty assets at 30 June; Q2 receipts from the franchise were flat at $194m. Weakness in this large exposure could weigh materially on collections. (Royalty Pharma, Royalty Pharma)
Debt principal was $9.2bn against $812m of cash at 30 June, and 2026 interest payments are forecast at $350m–$360m. These fixed outflows can constrain flexibility to fund acquisitions, repay debt or return capital. (Royalty Pharma)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Upcoming events
Royalty Pharma News
AllArticlesVideos
Funds containing Royalty Pharma
AllUSDEURGBP
Fund name | Fund size | $RPRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.81% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.81% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.50% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.50% |
SPDR MSCI World Health Care$WHEA | $708M | 0.29% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.